PRIMENA NESTEROIDNIH ANTIINFLAMATORNIH LEKOVA U HEMOPREVENCIJI KARCINOMA KOLONA

Aleksandra R Milić; Ivana Damnjanović

doi:10.5937/racter5-2352

Aleksandra R Milić Sandoz Pharmaceuticals Beograd
Ivana Damnjanović Medicinski fakultet, Univerzitet Niš

DOI: https://doi.org/10.5937/racter5-2352

Ključne reči: nonsteroidal antiinflammatory drugs||, ||nesteroidni antiinflamatorni lekovi, chemoprevention||, ||hemoprevencija, colorectal cancer||, ||kolorektalni karcinom,

Sažetak

Kolorektalni karcinom je po učestalosti na trećem mestu među malignim tumorima osoba oba pola u visoko razvijenim zemljama. To je predominantno bolest starijih ljudi, i javlja se uglavnom posle 60. godine života. Iako je etiologija karcinoma kolona nepoznata, pretpostavlja se da nastaje kao posledica kompleksne i nedovoljno razjašnjene interakcije genetskih faktora i činilaca spoljašnje sredine.

Osnovni element u etiologiji kolorektalnog karcinoma je proces genetskih promena u epitelnim ćelijama mukoze kolona. Smatra se da specifični epidemiološki faktori kao što su stres, hipoksija, redukovan unos glukoze i drugih nutricijenata, familijarna predispozicija za mutagene efekte, meso u ishrani, žučne kiseline, smanjen unos minerala i vitamina kao i promena pH fecesa dovode do započinjanja procesa kancerogeneze u mukozi debelog creva .

Hemoprevencija karcinoma se definiše kao upotreba hemijskog agensa sa ciljem da blokira, spreči ili odloži razvoj ili napredak karcinoma. Smatra se da je hemoprevencija jedna od glavnih komponenti kontrole karcinoma, a mnogobrojna istraživanja ukazuju na potencijalnu ulogu nesteroidnih antiinflamatornih lekova u hemoprevenciji karcinoma kolona.

Biografija autora

Aleksandra R Milić, Sandoz Pharmaceuticals Beograd

doktor medicine, specijalizant kliničke farmakologije

Reference

Bandaru S. The Fourth DeWitt S. Goodman lecture. Novel approaches to the prevention of con cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol Biomarkers Prev 2000; 9: 239-47.

Reddy BS, Maruyama H, Kelloff G. Dose related inhibition of colon carcinogenesis by dietary piroxi-cam, a non steroidal anti-inflamatory drug, during diferent stages of rat colon tumor devolepment. Cancer Res 1987; 47: 5340-6.

Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac a non steroidal anti-inflamatory agent. Cancer Res 1995; 55: 1464-72.

Chattopadhyay M, Velazquez CA, Pruski A, et al. Comparison between 3-Nitrooxyphenyl acetylsalicy-late (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASА) as safe anti-inflammatory, analgesic, antipyretic, antio-xidant prodrugs. J Pharmacol Exp Ther 2010; 335: 443-50.

Haddad A, Flint-Ashtamker G, Minzel W, Sood R, Rimon G, Barki-Harrington L. Prostaglandin EP1 receptor down-regulates expression of cyclooxyge-nase-2 by facilitating its proteasomal degradation. J Biol Chem 2012; 287: 17214-23.

Gupta K, Selinsky BS, Kaub CJ, Katz AK, Loll PJ. The 2.0 A resolution crystal structure of prostaglandin H2 synthase-1: structural insights into an unusual peroxidase. J Mol Biol 2004; 335: 503-18.

Caramia G. Essential fatty acids and lipid mediators. Endocannabinoids. Pediatr Med Chir 2012; 34: 65-72.

Meade EA, Smith EL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs. J Biol Chem 1993; 268: 6610-4.

Perić A, Toskić-Radojičić M. Analiza upotrebe i ispoljavanja neželjenih dejstava nesteroidnih anti-inflamatornih lekova: pilot studija. Vojnosanit Pregl 2006; 63: 271–7.

Samaha HS, Kelloff GJ, Vernon Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenyihexyl isothiocyanate: apoptotic Index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997; 57: 1301-5.

Fujino H, Toyomura K, Chen XB, Regan JW, Murayama T. Prostaglandin E₂ regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells. Biochem Pharmacol 2011; 81: 379-87.

Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83-7.

Brown JR, DuBois RN. COX-2: A Molecular Target for Colorectal Cancer Prevention. J Clin Oncol 2005; 23: 2840-55.

Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-50.

Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-9.

Benamouzing R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125: 328-36.

Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-9.

Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2007; 342: 1946-52.

Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131: 1674-82.

Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-84.

Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2009; 2: 310-21.

Guadagni F, Ferroni P, Palmirotta R, Del Monte G, Formica V, Roselli M. Non-steroidal Anti-inflamma-tory Drugs in Cancer Prevention and Therapy. Anti-canncer Res 2007; 27: 3147-62.

Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study. Lancet 2004; 363: 1751- 6